NYSE:TEVA - Teva Pharmaceutical Industries Stock Price, Price Target & More

Question 1

What is Teva Pharmaceutical Industries' stock symbol?

Answer

Teva Pharmaceutical Industries trades on the New York Stock Exchange (NYSE) under the ticker symbol "TEVA."

Question 2

How often does Teva Pharmaceutical Industries pay dividends? What is the dividend yield for Teva Pharmaceutical Industries?

Answer

Teva Pharmaceutical Industries announced a quarterly dividend on Thursday, November 2nd. Investors of record on Tuesday, November 28th will be paid a dividend of $0.085 per share on Tuesday, December 12th. This represents a $0.34 dividend on an annualized basis and a yield of 1.92%. The ex-dividend date is Monday, November 27th. View Teva Pharmaceutical Industries' Dividend History.

Question 3

How were Teva Pharmaceutical Industries' earnings last quarter?

Answer

Teva Pharmaceutical Industries (NYSE:TEVA) announced its quarterly earnings results on Thursday, February, 8th. The company reported $0.91 EPS for the quarter, topping analysts' consensus estimates of $0.77 by $0.14. The firm had revenue of $5.46 billion for the quarter, compared to the consensus estimate of $5.29 billion. Teva Pharmaceutical Industries had a positive return on equity of 16.43% and a negative net margin of 72.66%. The firm's quarterly revenue was down 15.9% compared to the same quarter last year. During the same quarter last year, the business posted $1.38 earnings per share. View Teva Pharmaceutical Industries' Earnings History.

Question 4

When is Teva Pharmaceutical Industries' next earnings date?

Answer

Teva Pharmaceutical Industries is scheduled to release their next quarterly earnings announcement on Thursday, May, 10th 2018. View Earnings Estimates for Teva Pharmaceutical Industries.

Question 5

What guidance has Teva Pharmaceutical Industries issued on next quarter's earnings?

Answer

Teva Pharmaceutical Industries updated its FY18 earnings guidance on Thursday, February, 8th. The company provided earnings per share (EPS) guidance of $2.25-2.50 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.99. The company issued revenue guidance of $18.3-18.8 billion, compared to the consensus revenue estimate of $19.36 billion.

Question 6

What price target have analysts set for TEVA?

Answer

27 analysts have issued 12-month price targets for Teva Pharmaceutical Industries' stock. Their predictions range from $11.00 to $41.00. On average, they anticipate Teva Pharmaceutical Industries' stock price to reach $19.8654 in the next year. View Analyst Ratings for Teva Pharmaceutical Industries.

Question 7

What are Wall Street analysts saying about Teva Pharmaceutical Industries stock?

Answer

Here are some recent quotes from research analysts about Teva Pharmaceutical Industries stock:

1. Maxim Group analysts commented, "Teva reported a better than expected quarter at $5.5B in revenues versus consensus at $5.3B, but we note revenues were down sequentially (3Q17: $5.6B). Generics came in at $3.1B and higher margin specialty at $1.8B. Copaxone in particular outperformed expectations, generating $821M, which is 34% greater than the $611M expected by the street. The beat on revenues followed through to non-GAAP EPS, which was $0.93, above expectations of $0.77." (2/8/2018)
2. According to Zacks Investment Research, "Teva is facing significant challenges in the form of generic competition for Copaxone, new competition for branded products, pricing erosion in the U.S. generics business, lower-than-expected contribution from new generic launches and a massive debt load. Also, Teva’s shares have underperformed the generic industry in the past one year. Mylan’s earlier-than-expected launch of the first generic version of the 40-mg strength of Copaxone was a major setback for Teva. Though Teva has divested some non-core assets to cut its significant debt load and aims to cut its global workforce by more than 25% over the next two years, a clear path to growth is not visible. Estimates have gone up ahead of the company’s Q4 earnings release due to expected cost savings from the restructuring plan. Teva has a negative record of earnings surprises. " (1/12/2018)
3. Cantor Fitzgerald analysts commented, "This morning Teva announced more details of its new strategic plan under CEO Kare Schultz, including the layoff of 14,000 people. This is meaningfully above the Street’s estimate of 10,000 jobs." (12/14/2017)
4. Jefferies Group LLC analysts commented, "MDCO announced early stoppage of the Ph 3 TANGO-2 trial for Vabomere (Carbavance) based on an interim analysis which showed a superior benefit-risk compared to best available therapy in serious infections due to CRE. We are impressed by DSMB stoppage of a trial with less than half of patients enrolled (72 out of the 150 target) suggesting a dramatic clinical benefit vs. standard of care. We believe today’s news provides a favorable setup for the August 21 (our estimate) PDUFA for Vabomere in cUTI. We continue to see Vabomere as a potential source of optionality for MDCO should management decide to launch this important new antibiotic on their own or in conjunction with a partner." (7/25/2017)

Question 8

Are investors shorting Teva Pharmaceutical Industries?

Answer

Teva Pharmaceutical Industries saw a drop in short interest in the month of March. As of March 29th, there was short interest totalling 59,397,239 shares, a drop of 9.1% from the March 15th total of 65,322,254 shares. Based on an average trading volume of 10,761,075 shares, the short-interest ratio is presently 5.5 days. Approximately 5.9% of the company's stock are short sold.

Question 9

Who are some of Teva Pharmaceutical Industries' key competitors?

Answer

Some companies that are related to Teva Pharmaceutical Industries include Regeneron (REGN), Astellas Pharma (ALPMY), Shiseido (SSDOY), Alexion Pharmaceuticals (ALXN), Mylan (MYL), UCB (UCBJF), Nektar Therapeutics (NKTR), BioMarin Pharmaceutical (BMRN), Grifols (GRFS), Genmab As (GNMSF), Perrigo (PRGO), Alnylam Pharmaceuticals (ALNY), Jazz Pharmaceuticals (JAZZ), BeiGene (BGNE), SAGE Therapeutics (SAGE), Alkermes (ALKS), Valeant Pharmaceuticals International (VRX) and Ionis Pharmaceuticals (IONS).

Question 10

Who are Teva Pharmaceutical Industries' key executives?

Answer

Teva Pharmaceutical Industries' management team includes the folowing people:

Mr. Michael McClellan, Exec. VP & CFO (Age 47)
Dr. Carlo de Notaristefani, Exec. VP of Global Operations (Age 60)
Mr. Mark Sabag, Exec. VP of Global HR (Age 47)
Dr. Hafrun Fridriksdottir, Exec. VP of Global R&D (Age 56)
Mr. Kåre Schultz, Pres, Chief Exec. Officer & Director (Age 57)

Question 11

Has Teva Pharmaceutical Industries been receiving favorable news coverage?

Answer

Press coverage about TEVA stock has trended somewhat positive this week, according to Accern Sentiment. Accern identifies positive and negative news coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Teva Pharmaceutical Industries earned a media sentiment score of 0.09 on Accern's scale. They also gave media stories about the company an impact score of 45.89 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near term.

Question 12

Who are Teva Pharmaceutical Industries' major shareholders?

Answer

Teva Pharmaceutical Industries' stock is owned by a number of of retail and institutional investors. Top institutional investors include ALLERGAN PLC (3.90%). Company insiders that own Teva Pharmaceutical Industries stock include Brendan P O'grady, Deborah A Griffin, Mark Sabag, Michael James Mcclellan, Richard Daniell and Sven Dethlefs. View Institutional Ownership Trends for Teva Pharmaceutical Industries.

Question 13

How do I buy shares of Teva Pharmaceutical Industries?

Answer

Shares of TEVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

Question 14

What is Teva Pharmaceutical Industries' stock price today?

Answer

One share of TEVA stock can currently be purchased for approximately $17.71.

Question 15

How big of a company is Teva Pharmaceutical Industries?

Answer

Teva Pharmaceutical Industries has a market capitalization of $18.22 billion and generates $22.39 billion in revenue each year. The company earns $-16,265,000,000.00 in net income (profit) each year or $3.93 on an earnings per share basis. Teva Pharmaceutical Industries employs 51,792 workers across the globe.

Question 16

How can I contact Teva Pharmaceutical Industries?

Answer

Teva Pharmaceutical Industries' mailing address is 5 BAZEL ST P O B 3190, PETACH TIKVA L3, 49131. The company can be reached via phone at 972-3926-7267 or via email at [email protected]

Community Ranking:		2.7 out of 5 ( )
Outperform Votes:		970 (Vote Outperform)
Underperform Votes:		844 (Vote Underperform)
Total Votes:		1,814

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Hold	Hold	Hold	Hold
Consensus Rating Score:	1.96	1.96	2.07	2.04
Ratings Breakdown:	7 Sell Rating(s) 14 Hold Rating(s) 6 Buy Rating(s) 0 Strong Buy Rating(s)	7 Sell Rating(s) 14 Hold Rating(s) 6 Buy Rating(s) 0 Strong Buy Rating(s)	5 Sell Rating(s) 16 Hold Rating(s) 7 Buy Rating(s) 0 Strong Buy Rating(s)	4 Sell Rating(s) 16 Hold Rating(s) 5 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$19.8654	$20.7963	$21.2654	$25.6625
Price Target Upside:	12.17% upside	16.12% upside	1.00% downside	72.23% upside

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
4/4/2018	Credit Suisse Group	Set Price Target	Buy	$23.00	High
3/26/2018	Royal Bank of Canada	Reiterated Rating	Hold	$16.00	Low
3/20/2018	Jefferies Group	Initiated Coverage	Hold -> Hold	$19.00	Medium
3/1/2018	Maxim Group	Reiterated Rating	Hold		Medium
2/13/2018	Wells Fargo	Reiterated Rating	Sell		Medium
2/9/2018	Bank of America	Lower Price Target	Underperform -> Underperform	$17.00 -> $16.00	Low
2/9/2018	Leerink Swann	Lower Price Target	Underweight -> Underperform	$17.00 -> $16.00	High
2/9/2018	Deutsche Bank	Lower Price Target	Hold -> Hold	$20.00 -> $18.00	Medium
2/9/2018	Gabelli	Downgrade	Buy -> Hold	$19.00	Medium
2/9/2018	Piper Jaffray	Downgrade	Neutral -> Underweight	$11.00	Medium
2/8/2018	Cantor Fitzgerald	Set Price Target	Hold	$18.00	Medium
2/8/2018	Oppenheimer	Reiterated Rating	Hold		Medium
2/2/2018	BTIG Research	Downgrade	Neutral -> Sell	$17.00	Low
1/25/2018	Susquehanna Bancshares	Reiterated Rating	Positive -> Positive	$22.00 -> $24.00	Medium
1/11/2018	Goldman Sachs	Boost Price Target	Buy	$20.00 -> $25.00	High
1/9/2018	Mizuho	Upgrade	Neutral -> Buy	$19.12 -> $23.00	N/A
1/4/2018	Citigroup	Upgrade	Neutral -> Buy	$24.00	Low
12/18/2017	UBS	Set Price Target	Hold	$12.00 -> $20.00	Low
12/15/2017	Morgan Stanley	Upgrade	Underweight -> Equal Weight	$18.00	Medium
12/12/2017	Guggenheim	Initiated Coverage	Neutral -> Neutral	$16.00	High
11/13/2017	JPMorgan Chase	Downgrade	Neutral -> Underweight	$11.48 -> $11.00	N/A
10/25/2017	Evercore ISI	Set Price Target	Buy	$38.00	N/A
10/20/2017	Barclays	Set Price Target	Hold	$21.00 -> $19.00	N/A
10/4/2017	Cowen	Reiterated Rating	Market Perform	$30.00 -> $18.00	N/A
9/21/2017	Sanford C. Bernstein	Lower Price Target	Mkt Perform -> Market Perform	$28.00 -> $20.00	Low
9/6/2017	JMP Securities	Boost Price Target	Underperform	$13.00 -> $14.00	Low
8/3/2017	CIBC	Reiterated Rating	Outperform -> Market Perform		High
2/28/2017	Argus	Downgrade	Buy -> Hold	$59.35 -> $31.90	N/A
9/29/2016	OTR Global	Initiated Coverage	Positive		N/A

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	2	$0.58	$0.63	$0.61
Q2 2018	2	$0.52	$0.59	$0.56
Q3 2018	2	$0.49	$0.55	$0.52
Q4 2018	2	$0.50	$0.51	$0.51

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
5/10/2018
2/8/2018	Q4 17	$0.77	$0.91	$5.2870 billion	$5.4590 billion	View	Listen
11/2/2017	Q3 2017	$1.03	$0.95	$5.6065 billion	$5.61 billion	View	N/A
8/3/2017	6/30/2017	$1.06	$0.99	$5.7168 billion	$5.6860 billion	View	Listen
5/11/2017	Q1 17	$1.06	$1.06	$5.6885 billion	$5.63 billion	View	N/A
2/13/2017	Q416	$1.36	$1.38	$6.26 billion	$6.25 billion	View	N/A
11/15/2016	Q316	$1.29	$1.31	$5.7132 billion	$5.56 billion	View	N/A
8/4/2016	Q216	$1.20	$1.25	$4.86 billion	$5.00 billion	View	N/A
5/9/2016	Q116	$1.17	$1.20	$4.78 billion	$4.81 billion	View	N/A
2/11/2016	Q415	$1.29	$1.28	$4.83 billion	$4.88 billion	View	Listen
10/29/2015	Q315	$1.28	$1.35	$4.75 billion	$4.80 billion	View	Listen
7/30/2015	Q215	$1.31	$1.43	$4.90 billion	$4.97 billion	View	Listen
4/30/2015	Q115	$1.26	$1.36	$4.84 billion	$5.00 billion	View	N/A
2/5/2015	Q414	$1.31	$1.31	$5.17 billion	$5.17 billion	View	N/A
10/30/2014	Q314	$1.23	$1.32	$5.09 billion	$5.06 billion	View	N/A
7/31/2014	Q214	$1.21	$1.23	$5.08 billion	$5.00 billion	View	N/A
5/1/2014	Q114	$1.22	$1.22	$5.11 million	$5.00 billion	View	N/A
2/6/2014	Q413	$1.26	$1.42	$5.19 billion	$5.40 billion	View	N/A
10/31/2013	Q313	$1.26	$1.27	$5.00 billion	$5.0590 billion	View	N/A
8/1/2013	Q213	$1.20	$1.20	$4.94 billion	$4.90 billion	View	N/A
5/2/2013	Q113	$1.10	$1.12	$4.85 billion	$4.90 billion	View	N/A
2/7/2013	Q412	$1.33	$1.32	$5.26 billion	$5.20 billion	View	N/A
11/1/2012	Q312	$1.25	$1.28	$5.08 billion	$5.00 billion	View	N/A
8/2/2012		$1.28	$1.28			View	N/A
5/9/2012		$1.44	$1.47			View	N/A
2/15/2012		$1.58	$1.59			View	N/A
11/2/2011		$1.22	$1.25			View	N/A
7/27/2011		$1.08	$1.10			View	N/A
5/11/2011		$1.03	$1.04			View	N/A
2/8/2011		$1.28	$1.25			View	N/A
11/2/2010	Q3 2010	$1.27	$1.30			View	N/A
7/26/2010	Q2 2010	$1.04	$1.08			View	N/A
5/4/2010	Q1 2010	$0.89	$0.92			View	N/A
2/16/2010	Q4 2009	$0.95	$0.94			View	N/A
11/3/2009	Q3 2009	$0.88	$0.89			View	N/A
7/28/2009	Q2 2009	$0.80	$0.83			View	N/A
5/5/2009	Q1 2009	$0.67	$0.72			View	N/A
2/17/2009	Q4 2008	$0.73	$0.76			View	N/A
11/6/2008	Q3 2008	$0.69	$0.72			View	N/A
7/29/2008	Q2 2008	$0.64	$0.65			View	N/A
5/6/2008	Q1 2008	$0.63	$0.64			View	N/A
2/12/2008	Q4 2007	$0.66	$0.69			View	N/A

Most Recent Dividend:	12/12/2017
Annual Dividend:	$0.43
Dividend Yield:	2.43%
Dividend Growth:	-14.40% (3 Year Average)
Payout Ratio:	10.94% (Trailing 12 Months of Earnings) 18.70% (Based on This Year's Estimates) 17.20% (Based on Next Year's Estimates)
Frequency:	Quarterly Dividend

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
11/2/2017	quarterly	$0.0850	2.74%	11/27/2017	11/28/2017	12/12/2017
8/7/2017	quarterly	$0.0850	1.83%	8/25/2017	8/29/2017	9/14/2017
5/11/2017	quarterly	$0.34	4.28%	6/1/2017	6/5/2017	6/22/2017
2/13/2017	quarterly	$0.34	3.7%	2/28/2017	3/2/2017	3/20/2017
11/15/2016	quarterly	$0.34		12/1/2016	12/5/2016	12/20/2016
8/4/2016	quarterly	$0.34		8/18/2016	8/22/2016	9/8/2016
5/9/2016	quarterly	$0.34		5/20/2016	5/24/2016	6/7/2016
2/16/2016	Quarterly	$0.2890		2/25/2016	2/29/2016	3/14/2016
10/29/2015	quarterly	$0.34		11/13/2015	11/17/2015	12/3/2015
7/30/2015	quarterly	$0.34		8/18/2015	8/20/2015	9/3/2015
5/5/2015	special	$0.34	2.25%	5/15/2015	5/19/2015	6/4/2015
2/5/2015	quarterly	$0.34	2.36%	2/17/2015	2/19/2015	3/3/2015
10/31/2014	special	$0.3210	2.43%	11/13/2014	11/17/2014	12/2/2014
8/1/2014	quarterly	$0.3530	2.61%	8/19/2014	8/21/2014	9/4/2014
5/2/2014	quarterly	$0.3470	2.77%	5/16/2014	5/20/2014	6/2/2014
2/4/2014		$0.34		2/20/2014	2/24/2014	3/10/2014
11/1/2013	quarterly	$0.3260	3.51%	11/18/2013	11/20/2013	12/2/2013
8/5/2013	quarterly	$0.3220	3.34%	8/16/2013	8/20/2013	9/3/2013
8/1/2013	quarterly	$0.3220			8/20/2013	9/2/2013
5/6/2013	special	$0.32	3.28%	5/16/2013	5/20/2013	6/3/2013
2/8/2013	quarterly	$0.31	3.21%	2/19/2013	2/21/2013	3/7/2013

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/19/2018	Deborah A Griffin	Insider	Sell	943	$17.88	$16,860.84
3/19/2018	Michael James Mcclellan	CFO	Sell	287	$17.88	$5,131.56
3/19/2018	Richard Daniell	VP	Sell	1,297	$17.89	$23,203.33	1,297
3/19/2018	Sven Dethlefs	EVP	Sell	571	$17.88	$10,209.48	5,016
3/5/2018	Brendan P O'grady	EVP	Sell	705	$19.38	$13,662.90
3/5/2018	Deborah A Griffin	Insider	Sell	773	$19.38	$14,980.74
3/5/2018	Richard Daniell	VP	Sell	1,108	$19.28	$21,362.24
2/15/2018	Mark Sabag	EVP	Sell	5,050	$19.68	$99,384.00	44,517

Date	Headline
	Global Cystic Fibrosis Therapeutics Market Overview 2017-2026: Teva Pharmaceutical Industries Ltd www.marketwatch.com - April 20 at 8:07 AM
	Teva Pharmaceutical Industries Ltd (TEVA) Receives Average Rating of "Hold" from Analysts www.americanbankingnews.com - April 19 at 5:56 PM
	Teva, Procter & Gamble to dissolve OTC partnership. finance.yahoo.com - April 19 at 5:54 PM
	BidaskClub Lowers Teva Pharmaceutical Industries (TEVA) to Hold www.americanbankingnews.com - April 19 at 12:49 PM
	Active Pharmaceutical Ingredient (API) Market is is Forecast to Cross US$ 219.00 Billion By 2023 www.marketwatch.com - April 19 at 8:02 AM
	BRIEF-Teva And P&G Have Agreed To Terminate The PGT Healthcare Partnership www.reuters.com - April 19 at 8:02 AM
	Teva and the Procter & Gamble Company Have Agreed to Terminate the PGT Healthcare Partnership finance.yahoo.com - April 19 at 8:02 AM
	P&G sales, earnings per share climb finance.yahoo.com - April 19 at 8:02 AM
	Heritage Pharma Announces Executive Leadership Changes www.prnewswire.com - April 18 at 5:57 PM
	Novartis’s 1Q18 Estimates: Expectations for Sandoz finance.yahoo.com - April 18 at 8:03 AM
	Teva Pharmaceutical Industries Ltd Forecasted to Earn Q1 2018 Earnings of $0.63 Per Share (TEVA) www.americanbankingnews.com - April 18 at 7:40 AM
	AbbVie’s Imbruvica in 4Q17 and Fiscal 2017 finance.yahoo.com - April 17 at 8:07 AM
	Teva to Present New Data Across Multiple Therapeutic Areas at 70th Annual Meeting of the American Academy of Neurology finance.yahoo.com - April 17 at 8:07 AM
	FY2021 EPS Estimates for Teva Pharmaceutical Industries Ltd Lowered by Leerink Swann (TEVA) www.americanbankingnews.com - April 17 at 7:05 AM
	Jefferies Group Reiterates Hold Rating for Teva Pharmaceutical Industries (TEVA) www.americanbankingnews.com - April 16 at 12:37 PM
	UPDATE 1-Israeli unions warn Teva Pharm over plan to close Ashdod plant www.reuters.com - April 16 at 8:03 AM
	Who Blinks First, Teva Or Histadrut? seekingalpha.com - April 16 at 8:03 AM
	Teva Pharmaceutical Industries Ltd (TEVA) Short Interest Update www.americanbankingnews.com - April 16 at 3:03 AM
	Israeli unions warn Teva Pharm over plan to close Ashdod plant finance.yahoo.com - April 15 at 8:51 AM
	Oppenheimer Downgrades Teva Pharmaceutical Industries (TEVA) to Market Perform www.americanbankingnews.com - April 13 at 6:01 PM
	Teva Pharmaceutical Industries (TEVA) PT Set at $39.00 by Credit Suisse Group www.americanbankingnews.com - April 13 at 6:01 PM
	UBS Downgrades Teva Pharmaceutical Industries (TEVA) to Market Perform www.americanbankingnews.com - April 13 at 6:01 PM
	US appeals court strikes down Maryland drug price-gouging law www.reuters.com - April 13 at 5:47 PM
	Teva Pharmaceutical Industries (TEVA) Stock Rating Reaffirmed by Credit Suisse Group www.americanbankingnews.com - April 12 at 2:52 PM
	Teva Pharmaceutical Industries (TEVA) Stock Rating Reaffirmed by Cantor Fitzgerald www.americanbankingnews.com - April 12 at 2:19 PM
	Jefferies Group Reaffirms Hold Rating for Teva Pharmaceutical Industries (TEVA) www.americanbankingnews.com - April 11 at 7:53 PM
	Deutsche Bank Reaffirms Buy Rating for Teva Pharmaceutical Industries (TEVA) www.americanbankingnews.com - April 11 at 7:53 PM
	Teva Pharmaceutical Industries (TEVA) Downgraded by Zacks Investment Research www.americanbankingnews.com - April 11 at 6:44 PM
	The Major Pharma Stocks That Are Making Short Sellers Sick www.msn.com - April 11 at 5:51 PM
	Are Drug Prices Too Low? finance.yahoo.com - April 11 at 8:07 AM
	Mylan to buy MS drug marketing rights from Israel's Mapi Pharma www.reuters.com - April 10 at 5:43 PM
	Teva Pharmaceutical’s Specialty Medicines Segment Performance finance.yahoo.com - April 10 at 8:09 AM
	Teva Pharmaceutical Industries' (TEVA) Neutral Rating Reiterated at Mizuho www.americanbankingnews.com - April 9 at 10:55 PM
	Teva Pharmaceutical Industries (TEVA) Downgraded to D+ at TheStreet www.americanbankingnews.com - April 9 at 7:30 PM
	Teva Pharm to close plant in Israel after no buyer found finance.yahoo.com - April 9 at 5:35 PM
	AssistRx co-founder: Why company took on Teva employees, lease in OP finance.yahoo.com - April 9 at 5:35 PM
	Teva Pharmaceutical Industries (TEVA) Upgraded to "Buy" by ValuEngine www.americanbankingnews.com - April 8 at 10:47 AM
	Analysts Anticipate Teva Pharmaceutical Industries Ltd (TEVA) Will Announce Quarterly Sales of $4.77 Billion www.americanbankingnews.com - April 6 at 4:32 AM
	Teva Pharmaceutical Industries (TEVA) Given a $23.00 Price Target by Credit Suisse Group Analysts www.americanbankingnews.com - April 5 at 11:20 AM
	Teva Pharmaceutical Industries (TEVA) PT Set at $38.00 by Evercore ISI www.americanbankingnews.com - April 4 at 9:36 PM
	Teva, Valeant Exposed By California's Drug Transparency Law seekingalpha.com - April 4 at 4:27 PM
	$0.67 Earnings Per Share Expected for Teva Pharmaceutical Industries Ltd (TEVA) This Quarter www.americanbankingnews.com - April 4 at 5:13 AM
	Teva Pharmaceutical Industries (TEVA) Stock Rating Reaffirmed by Mizuho www.americanbankingnews.com - April 4 at 12:34 AM
	Teva sells OP business segment finance.yahoo.com - April 3 at 5:46 PM
	Today’s Research Reports on Stocks to Watch: Alkermes and Teva finance.yahoo.com - April 3 at 5:46 PM
	Teva Pharmaceutical Industries (TEVA) Upgraded to "Strong-Buy" at ValuEngine www.americanbankingnews.com - April 2 at 11:26 PM
	How Novartis’s Cardio-Metabolic and Neuroscience Segments Performed finance.yahoo.com - April 2 at 8:06 AM
	Teva Pharmaceutical Industries (TEVA) Given a $18.00 Price Target by Cantor Fitzgerald Analysts www.americanbankingnews.com - March 31 at 12:42 PM
	Teva Pharmaceutical Industries (TEVA) Rating Increased to Hold at Zacks Investment Research www.americanbankingnews.com - March 31 at 10:56 AM
	CORRECTED-UPDATE 2-Teva wins reversal of U.S. jury's $235 mln GSK drug patent verdict www.cnbc.com - March 30 at 5:45 PM

NYSE:TEVA - Teva Pharmaceutical Industries Stock Price, Price Target & More

About Teva Pharmaceutical Industries (NYSE:TEVA)

Receive TEVA News and Ratings via Email

Industry, Sector and Symbol

Debt

Price-To-Earnings

Sales & Book Value

Profitability

Miscellaneous

Teva Pharmaceutical Industries (NYSE:TEVA) Frequently Asked Questions

What is Teva Pharmaceutical Industries' stock symbol?

How often does Teva Pharmaceutical Industries pay dividends? What is the dividend yield for Teva Pharmaceutical Industries?

How were Teva Pharmaceutical Industries' earnings last quarter?

When is Teva Pharmaceutical Industries' next earnings date?

What guidance has Teva Pharmaceutical Industries issued on next quarter's earnings?

What price target have analysts set for TEVA?

What are Wall Street analysts saying about Teva Pharmaceutical Industries stock?

Are investors shorting Teva Pharmaceutical Industries?

Who are some of Teva Pharmaceutical Industries' key competitors?

Who are Teva Pharmaceutical Industries' key executives?

Has Teva Pharmaceutical Industries been receiving favorable news coverage?

Who are Teva Pharmaceutical Industries' major shareholders?

How do I buy shares of Teva Pharmaceutical Industries?

What is Teva Pharmaceutical Industries' stock price today?

How big of a company is Teva Pharmaceutical Industries?

How can I contact Teva Pharmaceutical Industries?

MarketBeat Community Rating for Teva Pharmaceutical Industries (TEVA)

Analyst Ratings

Teva Pharmaceutical Industries (NYSE:TEVA) Price Target and Consensus Rating

Teva Pharmaceutical Industries (NYSE:TEVA) Consensus Price Target History

Teva Pharmaceutical Industries (NYSE:TEVA) Analyst Ratings History

Earnings

Teva Pharmaceutical Industries (NYSE:TEVA) Earnings History and Estimates Chart

Teva Pharmaceutical Industries (NYSE:TEVA) Earnings Estimates

Teva Pharmaceutical Industries (NYSE TEVA) Earnings History by Quarter

Dividends

Teva Pharmaceutical Industries (NYSE:TEVA) Dividend Information

Teva Pharmaceutical Industries (NYSE:TEVA) Dividend History by Quarter

Insider Trades

Teva Pharmaceutical Industries (NYSE TEVA) Insider Trading and Institutional Ownership History

Teva Pharmaceutical Industries (NYSE TEVA) Insider Trading History

Headlines

Teva Pharmaceutical Industries (NYSE TEVA) News Headlines

SEC Filings

Teva Pharmaceutical Industries (NYSE:TEVA) SEC Filings

Social Media

Financials

Teva Pharmaceutical Industries (NYSE:TEVA) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Teva Pharmaceutical Industries (NYSE TEVA) Stock Chart for Friday, April, 20, 2018